Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91513
Title:
Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations.
Authors:
Koltowska-Häggström, Maria; Mattsson, Anders F; Shalet, Stephen M
Abstract:
Quality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.
Affiliation:
KIMS Medical Outcomes, Pfizer Health AB, Endocrine Care, Sollentuna, Sweden. maria.koltowska-haggstrom@pfizer.com
Citation:
Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. 2009, 161 Suppl 1:S51-64 Eur. J. Endocrinol.
Journal:
European Journal of Endocrinology
Issue Date:
Nov-2009
URI:
http://hdl.handle.net/10541/91513
DOI:
10.1530/EJE-09-0266
PubMed ID:
19684056
Type:
Article
Language:
en
ISSN:
1479-683X
Appears in Collections:
All Christie Publications ; Endocrinology

Full metadata record

DC FieldValue Language
dc.contributor.authorKoltowska-Häggström, Mariaen
dc.contributor.authorMattsson, Anders Fen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-02-09T10:55:06Z-
dc.date.available2010-02-09T10:55:06Z-
dc.date.issued2009-11-
dc.identifier.citationAssessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. 2009, 161 Suppl 1:S51-64 Eur. J. Endocrinol.en
dc.identifier.issn1479-683X-
dc.identifier.pmid19684056-
dc.identifier.doi10.1530/EJE-09-0266-
dc.identifier.urihttp://hdl.handle.net/10541/91513-
dc.description.abstractQuality of life (QoL) has emerged as an important construct that has found numerous applications across healthcare-related fields, ranging from research and clinical evaluation of treatment effects to pharmacoeconomic evaluations and global healthcare policy. Impairment of QoL is one of the key clinical characteristics in adult GHD and has been extensively studied in the Pfizer International Metabolic Database (KIMS). We provide summarized evidence on GH treatment effects for both clinical and health economic applications based on the KIMS data. The primary focus is on those aspects of QoL research that cannot be investigated in the traditional clinical trial setting, such as specific patient subgroups, cross-country comparisons and long-term follow-up. First, the impact of age, gender, disease onset, primary aetiology, extent of hypopituitarism, previous radiotherapy and obesity on QoL before and during long-term GH replacement is discussed. Secondly, the studies on QoL in relation to country-specific normative values are reviewed. Finally, health economic data derived from KIMS including both burden of disease and utility assessment are evaluated. We conclude that the wide spectrum of analyses performed on the KIMS data allows for practical application of the results not only to research and clinical practice but also to health policy and global medical decision making.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAge Factors-
dc.subject.meshAged-
dc.subject.meshBiological Markers-
dc.subject.meshConfounding Factors (Epidemiology)-
dc.subject.meshDatabases, Factual-
dc.subject.meshDrug Costs-
dc.subject.meshFemale-
dc.subject.meshHealth Resources-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshHypopituitarism-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshInternational Cooperation-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshQuality of Life-
dc.subject.meshSex Factors-
dc.titleAssessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations.en
dc.typeArticleen
dc.contributor.departmentKIMS Medical Outcomes, Pfizer Health AB, Endocrine Care, Sollentuna, Sweden. maria.koltowska-haggstrom@pfizer.comen
dc.identifier.journalEuropean Journal of Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.